Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Payables: 2020-2024

Historic Payables for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $14.2 million.

  • Arcutis Biotherapeutics' Payables fell 70.01% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 million, marking a year-over-year increase of 14.16%. This contributed to the annual value of $14.2 million for FY2024, which is 18.58% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Payables of $14.2 million as of FY2024, which was up 18.58% from $12.0 million recorded in FY2023.
  • Arcutis Biotherapeutics' Payables' 5-year high stood at $14.2 million during FY2024, with a 5-year trough of $7.1 million in FY2020.
  • Over the past 3 years, Arcutis Biotherapeutics' median Payables value was $12.0 million (recorded in 2023), while the average stood at $11.7 million.
  • Data for Arcutis Biotherapeutics' Payables shows a peak YoY surged of 35.86% (in 2023) over the last 5 years.
  • Over the past 5 years, Arcutis Biotherapeutics' Payables (Yearly) stood at $7.1 million in 2020, then climbed by 2.98% to $7.4 million in 2021, then rose by 20.05% to $8.8 million in 2022, then skyrocketed by 35.86% to $12.0 million in 2023, then rose by 18.58% to $14.2 million in 2024.